Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
Zhan-Miao Yi,1–3 Ting-Ting Qiu,1,4 Yuan Zhang,5 Na Liu,6 Suo-Di Zhai1,3 1Department of Pharmacy, Peking University Third Hospital, 2Department of Pharmacy Administration and Clinical Pharmacy, Peking University School of Pharmaceutical Science, 3Institute for Drug Evaluation, Peking Unive...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/levodopacarbidopaentacapone-versus-levodopadopa-decarboxyiase-inhibito-peer-reviewed-article-TCRM |